Pharmaceutical company obtains FDA approval for imaging product
An Australian pharmaceutical company with a strong presence in central Indiana has reached an important milestone. Telix Pharmaceuticals Inc., with US headquarters in Fishers, has received US Food and Drug Administration approval for its lead prostate cancer imaging product.
According to Telix, Illuccix is a kit for the preparation of what is called PSMA-PET imaging, which is used to find lesions in certain patients with prostate cancer. The company claims that the product provides better flexibility and access to the imaging process.
This heralds a new era of patient and physician access to gallium-based PSMA-PET imaging and marks another important milestone for Telix as we bring our first commercial product to market in the United States,” said said Dr. Christian Behrenbruch, Managing Director. of Telix. “Enhanced imaging can provide physicians with the information needed to determine the most appropriate course of treatment and give patients in the United States access to a specific and sensitive imaging tool for the detection of prostate cancer in the whole body.”
Telix says it will be able to supply Illuccix to more than 85% of eligible PET imaging sites across the United States through its distribution network of more than 140 nuclear pharmacies.
In July, Telix announced plans to add 20 management and administrative positions to Fishers.